MedTrace Logo

Continuous Wound Infiltration for Diminution of Post-surgery Pain After Caesarean Section

NCT02828059 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2017-03-29

No results posted yet for this study

Summary

A medical approach that warrants continuous and reliable local administration of non-opioid analgesic drugs might substantially improve post-surgery pain management in CS, while decreasing the necessity of staff-dependent invasive procedures and the probability of untoward effects following systemic drug exposure. ReadyfusOR® is a formulation comprising a Ropivacain-loaded single-use pump which has been approved for regional application of the analgesic drug, also comprising obstetric interventions. There is, however, scarce scientific information on the efficacy and benefit of this anesthetic drug formulation for pain management following CS by means of continuous wound infiltration.

Conditions

Interventions

DRUG

Ropivacaine

Surgical wound Infiltration over 48 hours

Sponsors & Collaborators

  • Jena University Hospital

    lead OTHER

Principal Investigators

  • Ekkehard Schleussner, MD · Department of Obstetrics, Jena University Hospital

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-31
Primary Completion
2016-08-31
Completion
2016-08-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02828059 on ClinicalTrials.gov